The tuberculin skin test for immunologic diagnosis of Mycobacterium tuberculosis infection has many limitations, including being confounded by bacillus Calmette-Guérin (BCG) vaccination or exposure to nontuberculous mycobacteria. M. tuberculosis-specific antigens that are absent from BCG and most nontuberculous mycobacteria have been identified. We examined the use of two of these antigens, CFP-10 and ESAT-6, in a whole blood IFN-␥ assay as a diagnostic test for tuberculosis in BCG-vaccinated individuals. Because of the lack of an accurate standard with which to compare new tests for M. tuberculosis infection, specificity of the whole blood IFN-␥ assay was estimated on the basis of data from people with no identified risk for M. tuberculosis exposure (216 BCG-vaccinated Japanese adults) and sensitivity was estimated on the basis of data from 118 patients with culture-confirmed M. tuberculosis infection who had received less than 1 week of treatment. Using a combination of CFP-10 and ESAT-6 responses, the specificity of the test for the low-risk group was 98.1% and the sensitivity for patients with M. tuberculosis infection was 89.0%. The results demonstrate that the whole blood IFN-␥ assay using CFP-10 and ESAT-6 was highly specific and sensitive for M. tuberculosis infection and was unaffected by BCG vaccination status.
Tuberculosis continues to be a heavy burden on human health, with the World Health Organization estimating that one-third of the world's population is infected with Mycobacterium tuberculosis (1) . Detection and treatment of latent tuberculosis infection are important measures in the fight against this epidemic, especially in industrialized countries. The tuberculin skin test (TST) has been the only practical means of detecting latent M. tuberculosis infection in the past century. Unfortunately, the TST suffers from a number of well-documented performance and logistic problems, the most serious being false-positive responses due to reactivity caused either by infection with nontuberculous mycobacteria (NTM), or by bacillus Calmette-Gué rin (BCG) vaccination (2, 3) .
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Correspondence and requests for reprints should be addressed to Toru Mori protein derivative (PPD) was approved in the United States. Although this assay may be less affected by BCG vaccination than the TST (3), it is falsely positive in some BCG-vaccinated individuals (4) as many PPD antigens are similar or identical to antigens in BCG and NTM. Parts of the M. tuberculosis genome that are absent from the genomes of all BCG substrains and most NTM have been identified (5) . These M. tuberculosis-specific regions encode a number of proteins including CFP-10 and ESAT-6. Cell-mediated responses to these antigens have been shown to correlate with both proven M. tuberculosis infection and a high risk of infection (4, (5) (6) (7) (8) (9) (10) . The application of CFP-10 and ESAT-6 to the whole blood IFN-␥ assay should allow specific and sensitive diagnosis of M. tuberculosis infection in a relatively simple test format.
Thus, the aim of this study was to estimate the specificity and sensitivity of a whole blood IFN-␥ assay employing CFP-10 and ESAT-6, for the detection of M. tuberculosis infection in a predominantly BCG-vaccinated population. Estimates of sensitivity and specificity of tests for M. tuberculosis infection are hampered by the lack of a "gold standard"; one cannot prove the presence or absence of latent tuberculosis (TB) infection. In this study, sensitivity was determined in untreated patients with cultureproven tuberculosis, which although definitive for active tuberculosis requires extrapolation to equate to latent tuberculosis infection. Specificity was estimated in a group of BCG-vaccinated individuals with no known risks for M. tuberculosis exposure.
METHODS

Participants
Patients and student nurses consenting to the study were enrolled in Tokyo (National Tokyo Hospital, Fukujuji Hospital, and Japan AntiTuberculosis Association), Osaka (National Kinki Chuo Hospital and Osaka Prefectural Habikino Hospital), Chiba (National Chiba Higashi Hospital; and Nursing College, Chiba University), Miyazaki (Miyazaki Prefectural Nursing University), and Hiroshima (National Hiroshima Hospital), Japan after the protocol was approved by each institution's ethics review committee. Subjects were enrolled into one of two groups: Group 1 consisted of student nurses (older than 17 years of age) who were enrolled at the beginning of their training and had no identified risk for M. tuberculosis exposure; and Group 2 consisted of patients clinically suspected to have active tuberculosis and who had received less than 1 week of antituberculosis treatment.
After giving written consent, subjects were asked to complete a questionnaire about possible risk factors for exposure to M. tuberculosis. For low-risk subjects enrolled into Group 1, data were collected on their country of birth, history of prior tuberculosis or exposure to a person with tuberculosis, and other tuberculosis risk factors such as having an immunosuppressive condition (i.e., human immunodeficiency virus [HIV] , leukemia, lymphoma, diabetes mellitus, or renal failure) or having taken immune suppressive drugs in the 3 months before enrollment. Information regarding any previous Mantoux TST results and BCG vaccination status was also collected. For patients recruited into Group 2, information on their clinical symptoms of active tuberculosis and chest X-ray findings were collected at the time of enrollment. Sputum or other appropriate nonrespiratory samples were collected from Group 2 patients and cultured for mycobacteria.
Sample Collection and TST
A heparinized blood sample was collected for the whole blood IFN-␥ assay from each subject by venipuncture. Blood was collected before administration of Mantoux TSTs when the latter test was performed. For the TST, 0.1 ml of tuberculin PPD (Nippon BCG Manufacturing, Tokyo, Japan; equivalent to about 3 TU of PPD-S) was injected intradermally into the volar aspect of the forearm and transverse induration diameter was measured 48 hours later.
M. tuberculosis-specific Antigens
Pools of overlapping peptides representing CFP-10 and ESAT-6 were used as TB-specific antigens in the whole blood IFN-␥ assay. The sequence of six peptides representing CFP-10 and of seven peptides representing ESAT-6 are shown in Table 1 . Peptides, manufactured by either Mimotopes (Clayton, Australia) or Schafer-N (Copenhagen, Denmark), were at least 79% pure as determined by HPLC analysis. Peptides were solubilized in phosphate-buffered saline and aliquots (10 g/ ml for each peptide) were stored at Ϫ70ЊC, before use in the whole blood IFN-␥ assay.
Whole Blood IFN-␥ Assay
The whole blood IFN-␥ assay (QuantiFERON [QFT]; Cellestis, Carnegie, Australia) involves two stages: (1 ) overnight incubation of whole blood with antigens and (2 ) measurement of IFN-␥ production in harvested plasma samples by ELISA. Within 12 hours of collection, 1-ml aliquots of blood samples were dispensed into 24-well tissue culture plates and antigens were added to appropriate wells. Three drops of saline (nil control) or phytohemagglutinin (5 g/ml; mitogen-positive control), and 100 l of ESAT-6 or CFP-10 peptide cocktail, were added to separate wells to give a final peptide concentration of 1 g/ml. Blood samples were incubated with antigens for 16 to 24 hours at 37ЊC before harvesting about 300 l of plasma from above the settled blood cells.
The concentration of IFN-␥ in the four plasma samples from each subject was determined by QuantiFERON-CMI ELISA as per the manufacturer's instructions. This ELISA is reported by the manufacturer to have a limit of detection of 0.05 IU/ml for IFN-␥. Samples from up to 16 subjects were tested in each ELISA run, which also included a set of standards that were measured in duplicate. For an ELISA run to be valid, strict performance criteria (coefficient of variation less than 15% and correlation coefficient for the standard curve greater than 0.98) had to be met. ELISA data for the M. tuberculosisspecific antigens CFP-10 and ESAT-6 and the nil and mitogen controls were converted to international units per milliliter on the basis of the IFN-␥ standard curve generated for each ELISA plate. For an individual's test to be deemed valid, their response to at least one antigen (ESAT-6, CFP-10, or mitogen) had to be at least 0.25 IU of IFN-␥ per milliliter above that of their nil control (five times the limit of detection for the ELISA). Results for ESAT-6 and CFP-10 are expressed as the concentration of IFN-␥ detected minus the concentration of IFN-␥ in the respective nil control plasma.
Statistical Analysis
Information from the questionnaires, TST results, and whole blood IFN-␥ assay results was entered into Excel 2000 (Microsoft, Redmond, WA) and transferred to Stata version 7.0 (Stata, College Station, TX) for statistical analysis. Analysis consisted of t tests for differences in means based on logarithmic transformation of the IFN-␥ measurements, 2 test for testing difference in proportions, exact binomial methods to compute confidence intervals for proportions, and maximum-likelihood logistic regression to estimate the strength of the relation between age and response to the whole blood IFN-␥ assay and the TST.
RESULTS
Subjects were enrolled into the study over a 4-month period from July to October 2002. There were 216 people with no identified risk for M. tuberculosis exposure enrolled into Group 1 and 152 tuberculosis suspects enrolled into Group 2. The mean age for Group 1 subjects was 20 years (range, 18-33 years) and for Group 2, 54 years (range, 13-86 years; age was not recorded for eight people). Group 1 subjects were predominantly female (92.7%), whereas Group 2 subjects were predominantly male (66.4%). No subjects in Group 1 reported any history of contact with patients with tuberculosis or of working in any health care setting.
The majority of Group 1 subjects had last been screened with the TST when entering junior high school, 6 years before the current study. None of these subjects reported having an immunosuppressive condition such as HIV, leukemia, lymphoma, diabetes mellitus, or renal failure; and none reported having taken immune-suppressive drugs in the 3 months before enrollment. TST results were available for 113 of the 216 Group 1 subjects; of them, 97 (85.8%) had an induration 5 mm or more, 73 (64.6%) had an induration 10 mm or more, and 36 (31.9%) had an induration 15 mm or more. Thus, taking 10-mm induration as the cutoff, the specificity of tuberculin skin testing was 35.4%. The mean age and its standard error of those without TST were 19.5 years and 0.266, which compared with those with TST (19.2 and 0.238, respectively). All Group 1 subjects reported having received BCG vaccination at least once by the time of graduation from junior high school.
Of the 152 TB suspects in Group 2, 119 were proven to have M. tuberculosis infection (and active tuberculosis) by culture of the organism from sputum or other bodily samples. Sputum acidfast smear results were available for only 78 of the 119 persons with culture-proven tuberculosis, as one hospital did not report smear results. Sixty-eight of 78 patients had positive smears. One person, whose culture was positive for M. tuberculosis, had an indeterminate QFT result due to insufficient IFN-␥ production in response to the mitogen or TB-specific antigens. Results from this person were omitted from further analysis. M. tuberculosis was recovered from pleural fluid of four Group 2 subjects and from sputum of 114 subjects. All TB suspects had received less than 7 days of antituberculous chemotherapy at the time of testing; 95 (80.5%) had received none. TST results were available for 76 of the 118 evaluable Group 2 subjects; 50 of these (65.8%) displayed an induration of 5 mm or greater. The patients who had TST results had a mean age (Ϯ standard error) of 54.7 Ϯ 2.3 years, compared with 51.7 Ϯ 3.6 years for those in whom skin tests were not performed (p ϭ 0.74). Both groups had a similar sex distribution (65 and 66% males, respectively; p ϭ 0.96) and a similar percentage of patients with positive sputum acid-fast smears (92 and 82%, respectively; p ϭ 0.17).
No patients self-reported to be seropositive for HIV, undergoing hemodialysis, currently being treated with corticosteroids, or known to have a malignant disease. There were four patients with diabetes mellitus. There were 33 people in Group 2 whose cultures were negative for M. tuberculosis despite symptoms and suspicion of active tuberculosis; Mycobacterium avium complex (MAC) organisms were recovered from 5 of these people; Mycobacterium kansasii was recovered from 3; and 25 had negative culture results for mycobacteria.
Response to Specific Antigens
All IFN-␥ ELISA runs met the specified performance criteria and were deemed valid. The range of responses in the whole blood IFN-␥ assay for subjects in each study group are shown in Figure 1 . Patients with culture-proven tuberculosis had a significantly higher mean IFN-␥ response than did low-risk Group 1 subjects for both CFP-10 (geometric means being 0.657 and 0.010 IU/ml, respectively; p Ͻ 0.001) and ESAT-6 (1.330 and 0.003 IU/ml, respectively; p Ͻ 0.001). Table 2 shows test specificities and sensitivities for CFP-10 and ESAT-6 at various cutoff concentrations. To estimate specificity, all 216 subjects in Group 1 were assumed not to be infected with M. tuberculosis. To estimate sensitivity, only QFT results from the 118 Group 2 subjects for whom M. tuberculosis infection was confirmed by culture were used. To ascertain appropriate cutoffs for the ESAT-6 and CFP-10 antigens, receiver operating characteristic analysis was performed, based on data from Group 1 individuals for specificity and Group 2 patients with cultureconfirmed M. tuberculosis infection for sensitivity. Receiver operating characteristic analysis was performed with data from these subjects and confirmed that 0.35 IU/ml was an appropriate cutoff for both CFP-10 and ESAT-6. This cutoff was chosen to maximize specificity without significant loss of test sensitivity. Using this cutoff, the specificities (with 95% confidence intervals) for CFP-10 and ESAT-6 were 98.6% (96.0 to 99.7%; n ϭ 213, data for CFP-10 were unavailable for three people because of insufficient blood being collected) and 99.5% (97.5 to 100.0%; n ϭ 216), respectively, and the sensitivities were 65.3% (55.9 to 73.8%) and 81.4% (73.1 to 87.9%), respectively. If the data from CFP-10 and ESAT-6 were combined such that a person positive to at least one of the two antigens is judged as test positive, a sensitivity of 89.0% (81.9 to 94.0%) and a specificity of 98.1% (95.3 to 99.5%; n ϭ 213) were obtained. Test results were positive in 60 (88%) of 68 patients with positive sputum acid-fast smears and 6 (60%) of 10 patients with negative smears (p ϭ 0.07).
Data for the 33 people in Group 2 whose cultures were negative for M. tuberculosis despite symptoms and suspicion of active tuberculosis are shown in Figure 1C . For the 25 tuberculosis suspects from whom mycobacteria were not recovered, 56% (14) were positive to either CFP-10 or ESAT-6 in the whole blood IFN-␥ assay, a significantly smaller proportion as compared with those with culture-confirmed M. tuberculosis infection (89%; 2 test, p ϭ 0.0001). The whole blood IFN-␥ assay with either antigen was positive for all three patients from whom M. kansasii was recovered. For one of the five patients from whom MAC was recovered, the CFP-10 response was positive (IFN-␥, 7.5 IU/ml).
To examine the effect of age on sensitivity of the whole blood IFN-␥ assay and the TST, data from the 110 patients with confirmed tuberculosis, and whose ages were recorded, were stratified as shown in Table 3 . Logistic regression analyses were used to estimate the associations between age and QFT response, and between age and TST response. On average, persons were 0.83 times as likely to have a positive QFT and 0.71 times as likely to have a positive TST, compared with persons 10 years younger. The 95% confidence interval for the former odds ratio was 0.56 to 1.23, with decline being not statistically significant (p ϭ 0.35), and that for the latter was 0.53 to 0.94, with a statistically significant decline (p ϭ 0.015).
DISCUSSION
The current study demonstrates a high degree of accuracy in detecting M. tuberculosis infection, using the whole blood IFN-␥ assay with the M. tuberculosis-specific proteins CFP-10 and ESAT-6. The assay was shown to be highly specific (greater than 98%) in BCG-vaccinated low-risk subjects (Group 1) assumed to be truly free of M. tuberculosis infection. Specificity of the whole blood IFN-␥ assay was much better than the specificity observed for the TST in the present study (35.4%, using a 10-mm induration cutoff), or previously reported for Japan (10%) (11). Although we assumed that none of the Group 1 subjects were infected with M. tuberculosis, it is probable that some of the 216 subjects had been infected, as the prevalence of M. tuberculosis infection in 20-year-old people in Japan is estimated at 1% (12). Sensitivity was determined on the basis of data from 118 patients with culture-positive tuberculosis, and specificity was determined on the basis of data from 213 low-risk subjects. The chosen cutoff (0.35) is in boldface.
TABLE 2. TEST SENSITIVITY AND SPECIFICITY FOR CFP-10 AND ESAT-6 AT VARIOUS CUTOFFS IN WHOLE-BLOOD IFN-␥ ASSAY
Thus, the true specificity of the test may be higher than that estimated in the present study.
To estimate sensitivity of the whole blood IFN-␥ test, the presence of culture-confirmed M. tuberculosis infection was used as the standard. This approach has been widely used in sensitivity studies with the TST, often using patients who were receiving, or who had completed, treatment at the time of testing (3, (13) (14) (15) (16) . However, as it is well documented that both IFN-␥ responses can vary in relation to antituberculosis treatment (3, (17) (18) (19) , we limited this study to patients who had received minimal or no treatment at the time of testing. At the time of enrollment into the study, all 152 Group 2 subjects had radiologic and/or clinical signs suggesting tuberculosis and sensitivity was estimated from the 118 who had M. tuberculosis recovered subsequently by culture. Both ESAT-6 and CFP-10 demonstrated high positive rates in these patients (65.3 and 81.4%, respectively) as compared with that in tuberculin skin testing (65.8%). Combining results from the M. tuberculosis-specific antigens improved test sensitivity to 89.0% and had little effect on specificity (98.1%).
The poor skin test specificity of TST (35.4%) seen in this study is likely to be predominantly a result of the extensive use of BCG vaccination in Japan. However, poor skin test specificity may also be due to exposure or infection with NTM. Exposure to NTM, and not latent M. tuberculosis infection, appears to be responsible for the majority of 5-to 14-mm Mantoux test reactions among U.S.-born health care workers and medical students (20) . The present study was not designed to assess the specificity of the whole blood IFN-␥ assay after exposure to NTM. However, given the reported mycobacterial species specificity of ESAT-6 and CFP-10 (5), the assay is likely to be negative for infection with M. avium complex (MAC), which is a major source of NTM infection. This was compatible with the study's finding that IFN-␥ response to both of ESAT-6 and CFP-10 was negative in all patients who were culture negative for M. tuberculosis and positive for MAC, except one. The latter MAC patient with a positive IFN-␥ response could have coinfection with tuberculosis. On the other hand, positive reactions are expected from people infected with M. kansasii, Mycobacterium marinum, or Mycobacterium szulgai as the genes encoding both ESAT-6 and CFP-10 are present in these NTM (7) . Therefore, it is not surprising that another three TB suspects positive for M. kansasii responded to ESAT-6 and/or CFP-10 in the whole blood IFN-␥ assay. It remains to be confirmed whether the enhanced sensitivity of the whole blood IFN-␥ assay over the TST, as seen for untreated patients in this study, will also be found for people with latent tuberculosis infection. However, such a possibility can be supported by reports that contacts of patients with tuberculosis, who are possibly latently infected with M. tuberculosis, have stronger IFN-␥ responses to M. tuberculosis antigens than do patients with active tuberculosis (18, 19, (21) (22) (23) . Further investigations on the performance of the CFP-10/ESAT-6-based whole blood IFN-␥ assay in contact investigations and in other situations where M. tuberculosis exposure can be quantified are required to further estimate the test performance for detecting latent tuberculosis infection.
Screening for latent tuberculosis infection is most effective if those with positive test results are likely to progress to clinical disease. A preliminary study by Doherty and coworkers (24) demonstrated a close relationship between IFN-␥ responses and subsequent development of clinical tuberculosis disease in household tuberculosis contacts in Ethiopia, but this needs corroboration in other populations of different immune status and background. In addition, although the current study indicates utility of the IFN-␥ assay in screening adults for TB infection, further studies are required, including those in select patient populations such as children, people with X-ray evidence of prior tuberculosis, and those with HIV infection or other immunodeficiencies. Test utility would also be enhanced by studies determining the kinetics of IFN-␥ response after infection, and the effect of antituberculosis therapy on IFN-␥ test results.
Previous studies have demonstrated the potential of both ESAT-6 and CFP-10 for the specific detection of M. tuberculosis infection in humans (4, (5) (6) (7) (8) (9) (10) , although the method generally used to measure IFN-␥ responses to these antigens, such as lymphocyte proliferation and IFN-␥ enzyme-linked immunospot, are relatively complex and labor intensive to perform (25) . Some of these studies have demonstrated that a combination of results from ESAT-6 and CFP-10 provides higher sensitivity than is seen with either antigen alone (7, 8) . In addition, Vordermeier and coworkers demonstrated greater sensitivity with a cocktail of CFP-10 and ESAT-6 over either antigen alone, when used in an IFN-␥ enzyme-linked immunospot assay (26) , and Arend and coworkers showed that use of both antigens increased test sensitivity, as there were variations in responses to CFP-10 and ESAT-6 between individuals with different HLA-DR types (10) . These data suggest that the combined use of both TB-specific antigens is warranted to increase sensitivity and our results support this conclusion.
In addition to the high diagnostic accuracy resulting from the use of M. tuberculosis-specific antigens, the whole blood IFN-␥ assay offers many methodologic and logistic advantages, both over the TST and other laboratory methods of immunological testing. The test requires a single patient visit, does not induce boosting of subsequent test results, and can provide results within 1 day. Interreader variability is low and results are highly reproducible (27) as it is a controlled laboratory assay. Importantly, whole blood testing uses minimal labor and simple equipment, allowing large numbers of samples to be tested concurrently.
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